Waki, Yuhei
Morine, Yuji
Noma, Takayuki
Takasu, Chie
Teraoku, Hiroki
Yamada, Shinichiro
Saito, Yu
Ikemoto, Tetsuya
Shimada, Mitsuo
Funding for this research was provided by:
Japan Agency for Medical Research and Development (22fk0210103s0201)
Grant-in-Aid for Scientific Research (20K08957)
Taiho Pharmaceutical Co., Ltd.
Article History
Received: 11 April 2023
Accepted: 24 October 2023
First Online: 28 November 2023
Declarations
:
: This study was approved by the institutional review board of Tokushima University Hospital (approval no. 3215). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and the Helsinki Declaration of 1964 and later versions. Consent to participate was waived due to retrospective design of this study by Tokushima University Hospital Institutional Review Board.
: Not applicable.
: M.S. received research grants from Taiho Pharmaceutical CO., LTD., Chugai Pharmaceutical CO., LTD. and EPS Holdings, Inc., and scholarship donations from Taiho Pharmaceutical CO., LTD., Chugai Pharmaceutical CO., LTD., AbbVie GK., Johnson & Johnson K.K., Eisai Co., Ltd., Bayer Yakuhin, Ltd, Ono Pharmaceutical CO., LTD. and Takeda Pharmaceutical Co Limited. The other authors have no competing interests related to this study.